Market Research Industry Reports

Horizon Pharma Plc (HZNP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Horizon Pharma plc (Horizon Pharma) is a pharmaceutical company which develops and commercializes medical products for the treatment of pain, arthritis and inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. The companys marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid 2%, Procysbi, Quinsair, Ravicti, Rayos and Vimovo. Horizon Pharma provides products and services to patients and healthcare professionals in the US. The Company has offices in Deerfield, Lake Forest and Chicago, Illinois; Novato and Brisbane, California; Reinach, Switzerland; Utrecht, the Netherlands; and Mannheim, Germany. Horizon Pharma is headquartered in Dublin, Ireland.

Horizon Pharma Plc (HZNP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Horizon Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Horizon Pharma to Acquire Worldwide Rights to Interferon Gamma-1b from Boehringer Ingelheim for USD28.2 Million 15
Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 16
Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For US$51 Million 18
Vidara Therapeutics International Acquires Actimmune From InterMune For US$55 Million 20
Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 22
Venture Financing 23
River Vision Development Raises USD5 Million in Financing Round 23
River Vision Development Raises USD5.3 Million in Financing Round 24
River Vision Development Raises USD6 Million in Financing Round 25
River Vision Development Raises US$17 Million In Series A Financing 26
Hyperion Therapeutics Raises US$15 Million In Series D-II Financing 27
Private Equity 28
Vidara Therapeutics Raises Funds Through Private Equity Financing 28
Partnerships 29
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 29
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 30
Clinigen Group Partners with Horizon Pharma 31
Horizon Pharma Enters into Agreement with Alliance for Lupus Research 32
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 33
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 35
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 36
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 38
Licensing Agreements 40
Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 40
Horizon Pharma Enters into Licensing Agreement for Interferon Gamma-1b 41
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 42
Equity Offering 43
Horizon Pharma Raises USD499 million in Public Offering of Shares 43
Hyperion Therapeutics Files Registration Statement For Public Offering Of Securities For $150 Million 45
Hyperion Therapeutics Completes Public Offering Of Common Stock For US$69 Million 46
Horizon Pharma Completes Public Offering Of Units For US$86 Million 47
Hyperion Therapeutics Completes IPO For US$57.5 Million 48
Horizon Pharma Completes Private Placement Of Units For US$51 Million 49
Debt Offering 50
Horizon Pharma Raises USD300 Million in Private Placement of 8.75% Notes Due 2024 50
Horizon Pharma Raises USD475 Million in Private Placement of 6.625% Notes Due 2023 51
Horizon Pharma Raises USD400 Million in Private Placement of 2.5% Senior Notes Due 2022 53
Horizon Pharma Completes Private Placement Of Notes Due 2018 For US$150 Million 55
Asset Transactions 56
Horizon Pharma May Sell its Primary Care Drugs Business 56
Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 57
Acquisition 58
Horizon Pharma Acquires River Vision Development 58
Horizon Pharma Acquires Raptor Pharma in Tender Offer 59
Horizon Pharma May Sell Equity Stake in The Company 61
Horizon Pharma Acquires Crealta for USD510 Million 62
Horizon Pharma Acquires Hyperion Therapeutics for USD1.1 Billion 63
Horizon Pharma Acquires Vidara Therapeutics International for USD660 Million in Reverse Acquisition 65
Horizon Pharma Plc - Key Competitors 67
Horizon Pharma Plc - Key Employees 68
Horizon Pharma Plc - Locations And Subsidiaries 69
Head Office 69
Other Locations & Subsidiaries 69
Recent Developments 70
Financial Announcements 70
Feb 28, 2018: Horizon Pharma Announces Fourth-Quarter and Full-Year 2017 Results 70
Nov 06, 2017: Horizon Pharma Announces Third-Quarter and Year-to-Date 2017 Results 74
Aug 07, 2017: Horizon Pharma Announces Second-Quarter and Year-to-Date 2017 Results and Increases Full-Year 2017 Net Sales and Adjusted EBITDA Guidance 77
May 08, 2017: Horizon Pharma Announces First-Quarter 2017 Results and Revises Full-Year 2017 Net Sales and Adjusted EBITDA Guidance 81
Corporate Communications 84
Nov 30, 2017: Horizon Pharma Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer 84
Sep 11, 2017: Horizon Pharma Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer 85
Aug 03, 2017: Horizon Pharma Appoints Pascale Witz and James Shannon, M.D. to Board of Directors 86
Other Significant Developments 87
Jan 08, 2018: Horizon Pharma Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments 87
Mar 16, 2017: Horizon Pharma Announces "UCD in Common" for the Urea Cycle Disorder Community 90
Appendix 91
Methodology 91
About GlobalData 91
Contact Us 91
Disclaimer 91

List Of Tables

List of Tables
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Horizon Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Horizon Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Horizon Pharma to Acquire Worldwide Rights to Interferon Gamma-1b from Boehringer Ingelheim for USD28.2 Million 15
Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 16
Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For US$51 Million 18
Vidara Therapeutics International Acquires Actimmune From InterMune For US$55 Million 20
Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 22
River Vision Development Raises USD5 Million in Financing Round 23
River Vision Development Raises USD5.3 Million in Financing Round 24
River Vision Development Raises USD6 Million in Financing Round 25
River Vision Development Raises US$17 Million In Series A Financing 26
Hyperion Therapeutics Raises US$15 Million In Series D-II Financing 27
Vidara Therapeutics Raises Funds Through Private Equity Financing 28
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 29
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 30
Clinigen Group Partners with Horizon Pharma 31
Horizon Pharma Enters into Agreement with Alliance for Lupus Research 32
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 33
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 35
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 36
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 38
Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 40
Horizon Pharma Enters into Licensing Agreement for Interferon Gamma-1b 41
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 42
Horizon Pharma Raises USD499 million in Public Offering of Shares 43
Hyperion Therapeutics Files Registration Statement For Public Offering Of Securities For $150 Million 45
Hyperion Therapeutics Completes Public Offering Of Common Stock For US$69 Million 46
Horizon Pharma Completes Public Offering Of Units For US$86 Million 47
Hyperion Therapeutics Completes IPO For US$57.5 Million 48
Horizon Pharma Completes Private Placement Of Units For US$51 Million 49
Horizon Pharma Raises USD300 Million in Private Placement of 8.75% Notes Due 2024 50
Horizon Pharma Raises USD475 Million in Private Placement of 6.625% Notes Due 2023 51
Horizon Pharma Raises USD400 Million in Private Placement of 2.5% Senior Notes Due 2022 53
Horizon Pharma Completes Private Placement Of Notes Due 2018 For US$150 Million 55
Horizon Pharma May Sell its Primary Care Drugs Business 56
Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 57
Horizon Pharma Acquires River Vision Development 58
Horizon Pharma Acquires Raptor Pharma in Tender Offer 59
Horizon Pharma May Sell Equity Stake in The Company 61
Horizon Pharma Acquires Crealta for USD510 Million 62
Horizon Pharma Acquires Hyperion Therapeutics for USD1.1 Billion 63
Horizon Pharma Acquires Vidara Therapeutics International for USD660 Million in Reverse Acquisition 65
Horizon Pharma Plc, Key Competitors 67
Horizon Pharma Plc, Key Employees 68
Horizon Pharma Plc, Subsidiaries 69

List Of Figures

List of Figures
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Horizon Pharma Plc (HZNP) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Horizon Pharma plc (Horizon Pharma) is a pharmaceutical company which develops and commercializes medical products for the treatment of pain, arthritis and inflammatory diseases. It markets medicines through its orphan,

USD 250View Report

2018 US Coagulation Market Future Horizons and Growth Strategies: Analyzers and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Complete report $9,600.  DataPack (test volumes, sales forecasts, supplier shares) $6,200.This comprehensive report contains 424 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify

USD 9600View Report

N4 Pharma Plc (N4P) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

N4 Pharma Plc (N4 Pharma), formerly Onzima Ventures Plc is a pharmaceutical company that reformulates vaccines and drugs. The company provides generic products such as sartans, sildenafil, and aprepitant. It

USD 250View Report

Verona Pharma Plc (VRP) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Verona Pharma Plc (Verona Pharma) is a clinical-stage biotechnology company, which focuses on the research, discovery and development of first-in-class therapeutic drugs for the treatment of chronic respiratory and inflammatory

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :91
Country :Ireland
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube